Copyright
©The Author(s) 2025.
World J Gastroenterol. Aug 21, 2025; 31(31): 109828
Published online Aug 21, 2025. doi: 10.3748/wjg.v31.i31.109828
Published online Aug 21, 2025. doi: 10.3748/wjg.v31.i31.109828
Figure 1 Significant differences in microRNA expression and functional enrichment of primary biliary cholangitis with different ursodeoxycholic acid efficacy.
A: Scheme of overall study design; B: The number of differentially expressed microRNAs (miRNAs) before ursodeoxycholic acid treatment in the sensitive group and the resistance group. Up-regulated miRNAs are colored in red and down-regulated miRNAs are colored in blue; C: Volcano plot shows miRNAs that differ significantly between the two groups, based on fold change (drug sensitive pre-treatment vs drug resistance pre-treatment; drug sensitive post-treatment vs drug resistance pre-treatment) and P-value. In particular, blue (fold change < -1.25; P < 0.05) or red dots (fold change > 1.25; P < 0.05) indicate the presence of significantly downregulated or upregulated miRNAs, respectively. Gray dots were non-significantly different miRNAs; D: Clustering heatmap of pre-treatment differential miRNAs expression between resistant and sensitive groups. Red indicates upregulation and blue indicates downregulation. The columns and rows represent experimental SP samples and miRNAs, respectively; E: Clustering heatmap of differential miRNAs expression before and after treatment in the sensitive group; F: Gene Ontology enrichment analysis of differential miRNA target genes before ursodeoxycholic acid treatment in sensitive and resistance groups; G: Kyoto Encyclopedia of Genes and Genomes enrichment analysis of the differential miRNAs target genes. UDCA: Ursodeoxycholic acid; PBC: Primary biliary cholangitis; miRNA-seq: MicroRNA sequencing; RT-qRCR: Real-time quantitative polymerase chain reaction; DRpre: Drug resistance pre-treatment; DSpre: Drug sensitive pre-treatment; DSpost: Drug sensitive post-treatment.
Figure 2 Primary biliary cholangitis patients with high baseline miR-126-3p expression are sensitive to ursodeoxycholic acid, miR-126-3p expression was consistently upregulated after receiving ursodeoxycholic acid treatment and correlated with liver function.
A: Differentially expressed microRNAs (miRNAs) screened by sequencing were validated by quantitative real-time polymerase chain reaction in the discovery cohort; B: The top three differentially expressed folds of miRNAs from sequencing were selected in the test cohort for quantitative real-time polymerase chain reaction validation; C: Receiver operating characteristic curve analysis of miR-126-3p expression as a predictor of ursodeoxycholic acid efficacy; D: Comparison of miR-126-3p expression before and after treatment in primary biliary cholangitis patients in the test cohort; E: Correlation between miR-126-3p expression and liver function indexes. aP < 0.05; bP < 0.01; cP < 0.005; dP < 0.001. DRpre: Drug resistance pre-treatment; DRpost: Drug resistance post-treatment; DSpre: Drug sensitive pre-treatment; DSpost: Drug sensitive post-treatment; AUC: Area under the curve; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TBIL: Total bilirubin; IgG: Immunoglobulin G.
- Citation: Pan SD, Xiong CY, Shen YJ, Tian JH, Wang YL, Wang JN, Wang SY, Li FY, Wang LF, Qiu Q, Yang L, Liu XM, Luan JQ, Zou ZS, Wang FS, Meng FP. MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid. World J Gastroenterol 2025; 31(31): 109828
- URL: https://www.wjgnet.com/1007-9327/full/v31/i31/109828.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i31.109828